Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares PR Newswire SEATTLE, Dec. 13, 2017 SEATTLE, Dec. 13, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a...
PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding PR Newswire SEATTLE, Dec. 11, 2017 SEATTLE, Dec. 11, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical...
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency PR Newswire SEATTLE, Nov. 28, 2017 SEATTLE, Nov. 28, 2017 /PRNewswire/ -- PhaseRx, Inc...
PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire SEATTLE, Nov. 9, 2017 SEATTLE, Nov. 9, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a...
PhaseRx to Present at 5th International mRNA Conference PR Newswire SEATTLE, Oct. 31, 2017 SEATTLE, Oct. 31, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company...
PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options PR Newswire SEATTLE, Oct. 26, 2017 SEATTLE, Oct. 26, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a...
PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives PR Newswire SEATTLE, Oct. 13, 2017 SEATTLE, Oct. 13, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a...
PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency PhaseRx's second enzyme replacement therapy to receive orphan drug...
PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire SEATTLE, Aug. 10, 2017 SEATTLE, Aug. 10, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a...
PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update PR Newswire SEATTLE, May 12, 2017 SEATTLE, May 12, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 2255 | 1.0E-6 | CS |
| 52 | -0.000199 | -99.5 | 0.0002 | 0.0002 | 1.0E-6 | 1288 | 1.0E-6 | CS |
| 156 | -9.9E-5 | -99 | 0.0001 | 0.0003 | 1.0E-6 | 1891 | 0.00010963 | CS |
| 260 | -0.001799 | -99.9444444444 | 0.0018 | 0.1 | 1.0E-6 | 18286 | 0.01508543 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
